Abstract Purpose: Multiple myeloma is an incurable disease withheterogeneous clinical behavior.Bortezomib has offered some patients with relapsed and refractory disease an opportunity for prolonged survival. However, there remains apaucityofdatainpatients treatedwithbortezomibthataccurately delineates and identifies such patients.This information is crucial to guide management. Experimental Design: In this study, we aimed to identify the patients most likely to respond to bortezomib salvage therapy. We analyzed the baseline clinical variables and profiled the baseline expression of a broad range of immunohistochemical markers of cell cycle activity, apoptosis, and angiogenesis in a large cohort of multiply relapsed myeloma patients recruited to one of two prospective multicentre trials assessing the efficacy of bortezomib salvage therapy. Results: Using the European Group for Bone Marrow Transplantation criteria, response (complete or partial) to bortezomib salvage therapy was associated with a previous history of complete response to alternative antimyeloma treatment. Patients who expressed cyclin D1 were more likely to achieve a response. In contrast, patients who expressed p16
Multiple myeloma, a clonal malignancy of plasma cells, is still an incurable disease and accounts for 20% of all deaths from a hematologic malignancy (1) . However, marked clinical and biological heterogeneity within the disease exists with survival times varying from a few weeks to >20 years (2) . Understanding this heterogeneous clinical behavior has important consequences for guiding therapeutic decisions (3).
The median age at diagnosis is 70 years, with <30% of affected patients being aged <65 years. This age distribution is important as it often dictates the therapeutic regimes employed. Although high-dose chemotherapy and stem cell transplantation has shown the most promising results with regards to prolonging both time to progression (TTP) and overall survival (OS; refs. 4, 5) , many patients as a consequence of age and comorbidities are not eligible for this treatment strategy. Furthermore, nearly all the patients who receive high-dose chemotherapy and stem cell transplantation eventually relapse, necessitating the need for alternative therapeutic strategies. Novel agents such as bortezomib offer many of these patients the potential for long-term disease-free survival (2) .
The ubiquitin-proteasome pathway is responsible for the degradation of up to 80% of intracellular proteins (6) . Proteasomal inhibitors target several temporally and spatially diverse pathways within a malignant cell and have shown promise as antineoplastic agents (7) . Bortezomib, a proteasome inhibitor, has been proven to be efficacious in patients with multiple myeloma (8, 9) . Its therapeutic effects are mediated in part by an alteration of the cytokine milieu within the bone marrow and modification of the interaction between tumor and the surrounding stroma (10, 11) . Although the results with bortezomib are promising, work in identifying which patients are most likely to benefit is ongoing, with the data being limited primarily to clinical features and cytogenetics (12 -14) . There is a paucity of data from primary tissue samples of patients treated with bortezomib, which identifies and delineates the expression profiles of biomarkers known to have a fundamental role in the pathogenesis of multiple myeloma. This information is crucial to guide management.
To better demarcate the subset of patients that respond favorably to bortezomib, we performed an immunohistochemical panel on paraffin-fixed bone marrow biopsies (BMB) collected from patients enrolled in a clinical trial aimed at assessing the efficacy of bortezomib in patients with multiple myeloma. The immunohistochemical panel was chosen to include markers of cell cycle activity, apoptosis, and angiogenesis. Given that patients with t(4;14) multiple myeloma have been shown to have a poorer outcome with currently available therapies (15) , immunohistochemical was also done for FGFR3, which has been shown to correlate with t(4;14) and clinical outcome (16) .
Materials and Methods
Study population. The study comprised patients aged >18 years, who had been recruited to one of two multicenter international trials assessing the utility of bortezomib in relapsed and refractory multiple myeloma: the extended access program, an open-label, single-arm, noncomparative study of single-agent bortezomib (17) , and the DOXIL-MMY-3001, a prospective randomized study (18) . The eligibility, exclusion criteria, and treatment schedule have been presented previously (17, 18) . In brief, all patients included in this study received bortezomib at 1.3 mg/m 2 on days 1, 4, 8, and 11 of every 21-day cycle. Twenty-one of the patients received pegylated liposomal doxorubicin (30 mg/m 2 ) in addition to bortezomib on day 4 as part of the DOXIL-MMY-3001 study. Institution review boards at all participating institutions approved the study and all patients provided written informed consent. The biological specimens and clinical information was collected in a de-identified manner.
BMB specimens. All Australian centers participating in the aforementioned trials were invited to collaborate in this study. In addition to providing all the relevant clinical data, participating centers were requested to provide sufficient pathologic sample if a BMB was taken immediately before commencing bortezomib. Not all of the aforementioned trials required a BMB before trial entry. Only patients for whom there was sufficient pathologic sample of appropriate quality available for immunohistochemical studies were included.
Analysis of the bone marrow trephine sections. The H&E and immunohistochemical stains on the BMB sections were reviewed by three specialist pathologists (M.A.D., C.A.M., S.S.O.) and given a consensus score. Plasma cell infiltration of the entire BMB was scored in 10% increments based on morphologic assessment using both H&E section and CD138 immunostain. Each immunohistochemical stain was then assessed in reference to the number of plasma cells and scored in 10% increments according to the number of plasma cells positive for the immunostain. The presence and subcellular localization of the protein of interest were documented. The proportion of plasma cells positive for the protein was assessed as <25%, 25% to 50%, or >75%. When the protein of interest was expressed in virtually all the plasma cells in every patient studied (Bcl-2), an assessment of the staining intensity was made. This was graded as (a) normal intensity, (b) moderately strong intensity, or (c) very strong intensity. This was normalized to a control slide that was processed with each staining run. The immunostain was assessed as being absent if <10% of plasma cells were positive for the marker.
Immunohistochemistry. Immunohistochemistry was done on an automated immunostainer (Lab Vision Autostainer 360-2D; Lab Vision) according to the manufacturer's protocols. Paraffin-embedded BMB sections were decalcified and sequentially cut (3 Am thick sections), mounted, dewaxed, and immunostained. Peroxidase staining was done using Lab Vision UltraVision LP Large Volume Detection System HRP Polymer (Ready-to-Use). Antibodies were used according to the manufacturers' instructions and included anti-CD138 (clone MI15; DAKO), anti-cyclin D1 (clone SP4; Lab Vision), anti-Bcl-2 (clone 124; DAKO), anti-Bcl-xL (clone 2H12; Zymed), anti-p53 (clone DO-7; Novocastra), anti-p16 INK4A (clone 3G5D5; Zymed), anti-p21
(clone EA10; Zymed), anti-RelA (sc-109; Santa Cruz Biotechnology), anti-vascular endothelial growth factor receptor-1 (clone VG1; Zymed), anti-FGFR3 (sc-13121; Santa Cruz Biotechnology). Definition of outcomes. Patients were classified as achieving complete response (CR), partial response (PR), minimal response (MR), no change (NC), or progressive disease (PD) using the European Group for Bone Marrow Transplantation criteria (2) . In brief, PD requires 25% increase in paraprotein, whereas MR, PR, and CR require at least 25%, 50%, and 100% decreases, respectively. NC is the absence of progression or response. In this study, patients were classified as having a clinical response only if they achieved a CR or PR on therapy. Clinical response was treated as a categorical variable, whereas OS was treated as a censored continuous time variable. OS (days) was assessed from the date patients received their first dose of bortezomib.
Statistical analysis. Biological and clinical data were analyzed using Intercooled Stata version 9.2 (StataCorp.). Data were assessed for normality and log-transformed where appropriate. In the univariate analysis, continuous variables were assessed using Student's t test, nonparametric data using Wilcoxon rank-sum test, and categorical variables using Fisher's exact test. Multivariate analysis was done using multiple linear regression for normally distributed outcomes and multiple logistic regression for binomial outcomes. Multivariate models were constructed using a stepwise selection procedure and validated using a backwards elimination procedure. TTP and OS were assessed using the Kaplan-Meier method. A two-sided P = 0.05 was considered to be statistically significant. The comparison of the arms was based on the intention-to-treat principle and used the available data on all patients. Median potential follow-up in each arm was estimated using date from clinical questionnaire completion (censored by progression and death).
Translational Relevance
The success of bortezomib in patients with multiple myeloma varies considerably. It offers some patients a substantial survival benefit, whereas others receive all of the incumbent side effects with no benefit in disease-free or overall survival. Furthermore, the cost of such agents to national health care systems is substantial. Currently, there are limited data to guide clinicians on which patients to target with this therapy. In our study done in a large cohort from two prospective multicentre trials, we were able to stratify patients likely to respond based on a panel of immunohistochemical and clinical variables that are easily accessible to all clinicians at the time of making clinical decisions. Although the response and methodology employed in this study warrant validation in larger prospective studies before being widely embraced, this is the first study that offers guidance to clinicians on the rational use of bortezomib in relapsed myeloma patients using routine clinical information and diagnostic tools.
Results
Patient characteristics. Overall, 89 patients with relapsed multiple myeloma who received bortezomib as salvage therapy were recruited to this study. Three patients only received one cycle of bortezomib and were therefore excluded from the response analysis. A summary of the demographic details is presented in Table 1 . This was a heavily pretreated cohort with a median of three previous therapies and 79% of patients had undergone a transplant before bortezomib salvage. The majority of patients had attained a poor clinical response to previous therapies with only 8 (9%) patients having attained a prior CR. The median follow-up for the entire cohort at the time of analysis was 11 months (range, 1-20 months).
Clinical variables associated with response. In this study, the overall response rate was 52%, with 12 (14%) patients achieving a CR (Table 2) . Clinical response was not associated with gender or age before receiving bortezomib. The main clinical correlate that predicted outcome was the patient's best response to prior multiple myeloma therapy ( Table 1) . All of the patients who had previously attained a CR achieved a clinical response with bortezomib salvage therapy (P = 0.02). A previous response that was less than a CR did not predict for outcome with bortezomib. Of note, a clinical response was seen in patients from all subgroups including those who had never achieved an objective response with prior multiple myeloma therapies (Table 1) . Baseline blood counts (full blood counts, renal function, and liver function tests; data not shown) and biomarkers including h 2 -microglobulin, albumin, lactate dehydrogenase, paraprotein level or type, and light chain-only disease were not predictive of outcome with bortezomib (Table 1) . In this study, the addition of pegylated liposomal doxorubicin to bortezomib was not associated with a statistically significant difference in clinical response; this finding is consistent with those from the larger international study (18) . Immunohistochemical variables associated with response. Histologic assessment of BMB and the full panel of immunohistochemical markers were done on all 89 patients. Although morphologic assessment (H&E) and quantitative analysis (CD138) showed a wide range of plasma cell infiltration and a spectrum of morphologic variants including plasmablasts and plasma cell aggregates, these features were not predictive of outcome to bortezomib salvage therapy. A semiquantitative assessment of the expression of each marker was recorded as per the study design; however, in the majority of cases, response was not associated with subtle variations in the quantitative or qualitative expression of these proteins. The most important information with regards to predicting response was the presence or absence of these markers and the subcellular localization of the proteins of interest (Fig. 1) . Fig. 1 ). Virtually all of the patients in this cohort showed expression of Bcl-2 within their malignant plasma cells; however, the intensity of staining for this protein showed substantial variation (Table 3 ; Fig. 1 ). When analyzed for response, patients with highest intensity of Bcl-2 staining were less likely to attain a clinical response with bortezomib (OR, 0.67; P = 0.02). The detection of cyclin D1 in the nuclei of malignant plasma cells was associated with a trend to significance for predicting a better response to bortezomib (OR, -2.21; P = 0.07).
The presence, subcellular localization, proportion of plasma cells expressing the protein, and intensity of staining for Bcl-xL, RelA, vascular endothelial growth factor, or p21 CIP/WAF1 were not predictive of outcome to salvage therapy with bortezomib. Patients whose myeloma cells express FGFR3 responded equally well to salvage therapy than those without this adverse prognostic marker (Table 3 ; Fig. 1 ).
Subset analyses. The negative prognosis imparted by c-p53 and p16
INK4A staining was improved in the presence of concurrent cyclin D1 staining; conversely, the good prognosis imparted by cyclin D1 staining was abrogated by the presence of either c-p53 or p16 INK4A (Table 4 ). In the absence of cyclin D1, only 14% and 34% of patients in this cohort responded to bortezomib when positive for c-p53 or p16 INK4A , respectively. In contrast, in the absence of either c-p53 or p16 INK4A , response rates were 68% and 80%, respectively, for those patients with cyclin D1 staining. Furthermore, when cyclin D1 was present in the absence of both c-p53 and p16
INK4A
, all but one of these patients responded to bortezomib.
Survival analysis. Median follow-up was 11 months in each arm (no response to bortezomib and response to bortezomib). In this study, the median TTP for nonresponders (n = 40) was 4.9 months compared with responders (n = 46) at 9 months (P = 0.001; hazard ratio, 0.47; 95% confidence interval, 0.28-0.79; Fig. 2A ). The median OS for nonresponders was 15 months. In comparison, the median OS for responders has not been reached at the time of analysis (P = 0.0004; hazard ratio, 6.7; 95% confidence interval, 2-25; Fig. 2B ). There was no statistical difference in the TTP for patients when stratified for the expression of the various immunohistochemical biomarkers. In addition, the TTP for patients receiving bortezomib alone was no different when compared with those receiving bortezomib plus pegylated liposomal doxorubicin. This finding is different to the international study and likely reflects the larger number of patients required to show significant changes in progression-free survival with the addition of pegylated liposomal doxorubicin. The OS of patients expressing nuclear cyclin D1 was superior to those patients in which this marker was absent (P = 0.05; hazard ratio, 3.1; 95% confidence interval, 1.0-11.1; Fig. 2C ). In the 23% of the cohort that expressed FGFR3, the median TTP was 7 months compared with 8 months for FGFR3-negative patients (P = 0.87; hazard ratio, 0.95; 95% confidence interval, 0.52-1.7) and the OS for these patients was not inferior to the rest of the cohort (P = 0.91; hazard ratio, 1.1; 95% confidence interval, 0.36-3.19; Fig. 2D and E).
Discussion
Multiple myeloma is a heterogeneous disease whose management continues to evolve in the face of new drug development. In this study, we evaluated a cohort of relapsed multiple myeloma patients receiving bortezomib as salvage therapy for clinical and immunohistochemical features that predicted response to bortezomib. Although we are aware that some studies have reported a clinical benefit in patients who achieved a MR to bortezomib in the relapsed setting (9, 19) , we chose to analyze this cohort using the more stringent response criteria of CR or PR. A clinically meaningful response (CR + PR) was seen in 52% of the overall cohort and this response translated to a significant survival advantage.
The main clinical variable that predicted response to bortezomib therapy was a history of a previous CR to multiple myeloma therapy. However, as patients who had previously never achieved an objective response to multiple myeloma therapy also achieved clinically meaningful responses to salvage therapy, this clinical variable in isolation is inadequate to guide clinicians in patient selection. We further evaluated a panel of immunohistochemical markers that are easily accessible and interpretable by a hematopathologist to better delineate the responders. Our results show that immunohistochemical detection of p16 INK4A and c-p53 demarcate a group of patients that respond poorly to bortezomib. Furthermore, patients with the highest staining intensity for Bcl-2 also responded poorly. In contrast, the patients in whom nuclear cyclin D1 expression is identified by immunohistochemistry represent a group of patients more responsive to bortezomib. Patients whose myeloma express FGFR3, a documented adverse prognostic marker associated with t(4;14), responded equally well to bortezomib salvage therapy and had similar outcomes from therapy than those without FGFR3 expression. Bortezomib is the first antimyeloma therapy to show equal therapeutic benefit for this adverse prognostic group, suggesting that these patients who do poorly with conventional therapies may be better treated with novel agents such as this. The precise molecular mechanisms explaining the poor prognosis conferred by expression of p16
INK4A and c-p53 are currently unknown. Deletions and point mutations of p53 and p16
INK4A are rarely seen in myeloma, except with advanced disease (20 -22) . Our results with regards to the cytoplasmic localization of p53 are especially interesting, as a recent study showed that although mutations in p53 are rare, they confer a very poor prognosis. In keeping with our findings of a poor Fig. 2 . Kaplan-Meier plots for response to bortezomib. A, TTP of the disease in the 89 patients in this cohort as stratified by response to bortezomib salvage. B, OS in patients who responded to bortezomib salvage was markedly superior to nonresponders, with the median survival not being reached at the time of analysis. C, OS when stratified by staining for cyclin D1, the main positive predictive marker for response to bortezomib shows a survival advantage for those patients expressing cyclin D1. TTP (D) and OS (E) for the patients expressing FGFR3 were not inferior to the rest of the cohort following salvage therapy with bortezomib. prognosis seen in patients with c-p53, the majority of patients in this study had mutations that disrupted the nuclear localization of p53 and its ability to bind DNA (21) . p16
INK4A is a key regulator of the G 1 -S interface (23) . Its role in the molecular pathogenesis of multiple myeloma is not clear. Recent literature suggests that although mutations or loss of p16
INK4A by promoter methylation were thought to be a late progression event in multiple myeloma, most human multiple myeloma tumors and cell lines actually continue to highly express p16 INK4A regardless of methylation status (22, 24) . Our immunohistochemical findings further support these recent studies. It is increasingly being recognized that many of the cytotoxic and cytostatic effects of bortezomib may be cell cycle specific. It is therefore conceivable that the differential expression of key regulators of the cell cycle including p16
INK4A may confer varied susceptibility to bortezomib (25, 26) . Finally, virtually all myeloma cell lines and primary tumor cells overexpress proteins from the Bcl-2 family (27, 28) . The overexpression of Bcl-2 has been shown in cell lines to decrease the efficacy of bortezomib (10) . In keeping with this, the patients in our cohort who showed the highest intensity of staining with Bcl-2 were less likely to respond to bortezomib.
The expression of nuclear cyclin D1 was associated with a favorable response to bortezomib. Overexpression of cyclin D1 seen in up to 60% of multiple myeloma primary tumor cells is due to either t(11;14)(q13;q32) or induced expression from the interaction of multiple myeloma cells with the surrounding bone marrow stroma (27) . The evidence linking overexpression of cyclin D1 with prognosis in myeloma shows conflicting results (29 -35) . However, none of these studies examined protein expression specifically. Cyclin D1 is rapidly degraded by the 26S proteasome and bortezomib has been shown to increase levels of cyclin D1 potentiating its activity in vivo (36) . Recent literature shows that cyclin D1 levels inversely correlate with STAT-3 levels, resulting in downstream effects that increase the susceptibility of cells to apoptosis (36, 37) . In accordance with this notion, we have shown that the expression of nuclear cyclin D1 within myeloma cells confers a better response to bortezomib. Further clinical evidence in support of our findings is the demonstrated efficacy of bortezomib in patients with mantle cell lymphoma, a disease characterized by the overexpression of cyclin D1 (38) .
The TTP and OS data reinforce the importance of being able to predict a meaningful response to bortezomib. Although it is not surprising that response afforded patients a survival advantage, what is unexpected and noteworthy is the magnitude of this advantage. Patients who achieved a CR or PR to bortezomib salvage had a marked survival advantage over nonresponders; indeed, for the first time, we have shown that recognizing patients with good prognostic markers such as cyclin D1 can identify a large subset of this cohort who should be targeted for bortezomib therapy.
A recent study attempted to address the issue of prognostic indicators for response to bortezomib using a DNA microarray platform to study gene expression from samples collected during several large multicenter trials (39) . Although this is a powerful method of analysis, there are several pitfalls associated with it. It is often difficult even in the context of a carefully planned clinical trial to obtain an adequate sample for gene expression profiling (39) . The data generated from gene expression profiling take a substantial amount of time and expertise to analyze (39) ; most importantly, gene expression profiling is still largely a research tool and is not available to the vast majority of clinicians and pathologists to guide their daily practice. The strength of this study is that we have been able to stratify patients and identify factors that predict for response to bortezomib using clinical variables and a panel of immunohistochemical markers that are easily accessible to all clinicians at the time of making therapeutic decisions. Furthermore, this study serves to highlight the potential of targeting combination therapies to patients with known poor prognostic markers from the outset based on their clinical features and immunohistochemical expression profiles. Combination therapies using novel agents have revolutionized the treatment of multiple myeloma in the early stages as well as in the relapse setting (40 -43) . The challenge ahead for clinicians is the rational choice of these therapies that are individually catered to the patient; prognostic tools such as those used in this study may prove valuable to guide treatment choices.
The main limitation of this study is the heterogeneous patient population. This is presently unavoidable and has been encountered by other investigators (39), aiming to get sufficient patients to address issues related to prognostication. Further consideration should now be given to the incorporation of an immunohistochemical assessment of BMB in future prospective trials, assessing the efficacy of bortezomib or other novel agents in patients with multiple myeloma.
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